MAGE-A family: Attractive targets for cancer immunotherapy

Vaccine

Volumn 29, Issue 47, 2011, Pages 8496-8500

  Sang, Meixiang ^a   Lian, Yishui ^a   Zhou, Xinliang ^a   Shan, Baoen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cancer immunotherapy; Cancer testis antigens; MAGE A

Indexed keywords

GENE PRODUCT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; GENE ACTIVATION; GENE TARGETING; GENETIC CODE; GERM CELL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TESTIS;

CANCER VACCINES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOTHERAPY; MELANOMA-SPECIFIC ANTIGENS; NEOPLASMS;

EID: 82455175361     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.014     Document Type: Review

References (57)

1. Zendman A.J., Ruiter D.J., Van Muijen G.N. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003, 194:272-288.
2. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T., Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005, 5:615-625.
3. Scanlan M.J., Simpson A.J., Old L.J. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004, 23:1.
4. Van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
5. Traversari C., Van der Bruggen P., Van den Eynde B., Hainaut P., Lemoine C., Ohta N., et al. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 1992, 35:145-152.
6. De Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.P., De Smet C., et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994, 40:360-369.
7. Chomez P., De Backer O., Bertrand M., De Plaen E., Boon T., Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001, 61:5544-5551.
8. Suri A. Cancer testis antigens - their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther 2006, 6:379-389.
9. Ries J., Mollaoglu N., Toyoshima T., Vairaktaris E., Neukam F.W., Ponader S., et al. A novel multiple-marker method for the early diagnosis of oral squamous cell carcinoma. Dis Markers 2009, 27:75-84.
10. Hussein Y.M., Gharib A.F., Mohamed R.H., Radwan M.I., Elsawy W.H. MAGE-3 and MAGE-4 genes as possible markers for early detection of metastases in hepatitis C virus Egyptian patients complicated by hepatocellular carcinoma. Med Oncol 2011, 31.
11. Hussein Y.M., Gharib A.F., Etewa R.L., EI-Shal A.S., Abdel-Ghany M.E., Elsawy W.H. The melanoma-associated antigen-A3, -A4 genes: relation to the risk and clinicopathological parameters in breast cancer patients. Mol Cell Biochem 2011, 351:261-268.
12. Forghanifard M.M., Gholamin M., Farshchian M., Moaven O., Memar B., Forghani M.N., et al. Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: Identification of specific tumor marker and potential targets for immunotherapy. Cancer Biol Ther 2011, 12:191-197.
13. Ohman Forslund K., Nordqvist K. The melanoma antigen genes - any clues to their functions in normal tissues?. Exp Cell Res 2001, 265:185-194.
14. Barker P.A., Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 2002, 67:705-712.
15. Rogner U.C., Wilke K., Steck E., Korn B., Poustka A. The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics 1995, 29:725-731.
16. Doyle J.M., Gao J., Wang J., Yang M., Potts P.R. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell 2010, 39:963-974.
17. Espantman K.C., O'Shea C.C. aMAGEing new players enter the RING to promote ubiquitylation. Mol Cell 2010, 39:835-837.
18. Brasseur F., Rimoldi D., Liénard D., Lethé B., Carrel S., Arienti F., et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995, 63:375-380.
19. Jang S.J., Soria J.C., Wang L., Hassan K.A., Morice R.C., Walsh G.L., et al. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res 2001, 61:7959-7963.
20. Otte M., Zafrakas M., Riethdorf L., Pichlmeier U., Löning T., Jänicke F., et al. MAGE-A gene expression pattern in primary breast cancer. Cancer Res 2001, 61:6682-6687.
21. Lin J., Lin L., Thomas D.G., Greenson J.K., Giordano T.J., Robinson G.S., et al. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants. Clin Cancer Res 2004, 10:5708-5716.
22. Bergeron A., Picard V., LaRue H., Harel F., Hovington H., Lacombe L., et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 2009, 125:1365-1371.
23. Suyama T., Ohashi H., Nagai H., Hatano S., Asano H., Murate T., et al. The MAGE-A1 gene expression is not determined solely by methylation status of the promoter region in hematological malignancies. Leuk Res 2002, 26:1113-1118.
24. Busam K.J., Iversen K., Berwick M., Spagnoli G.C., Old L.J., Jungbluth A.A. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol 2000, 13:459-465.
25. Rimoldi D., Salvi S., Schultz-Thater E., Spagnoli G.C., Cerottini J.C. Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int J Cancer 2000, 86:749-751.
26. Picard V., Bergeron A., Larue H., Fradet Y. MAGE-A9 mRNA and protein expression in bladder cancer. Int J Cancer 2007, 120:2170-2177.
27. Schultz-Thater E., Piscuoglio S., Iezzi G., Le Magnen C., Zajac P., Carafa V., et al. MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. Int J Cancer 2011, 129:1137-1148.
28. Sang M., Wang L., Ding C., Zhou X., Wang B., Wang L., et al. Melanoma-associated antigen genes-an update. Cancer Lett 2011, 302:85-90.
29. De Smet C., Courtois S.J., Faraoni I., Lurquin C., Szikora J.P., De Backer O., et al. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics 1995, 42:282-290.
30. De Smet C., Lurquin C., Lethé B., Martelange V., Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999, 19:7327-7335.
31. Wischnewski F., Pantel K., Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006, 4:339-349.
32. Weeraratne S.D., Amani V., Neiss A., Teider N., Scott D.K., Pomeroy S.L., et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol 2011, 13:165-175.
33. Duan Z., Duan Y., Lamendola D.E., Yusuf R.Z., Naeem R., Penson R.T., et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 2003, 9:2778-2785.
34. Laduron S., Deplus R., Zhou S., Kholmanskikh O., Godelaine D., De Smet C., et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 2004, 32:4340-4350.
35. Monte M., Simonatto M., Peche L.Y., Bublik D.R., Gobessi S., Pierotti M.A., et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 2006, 103:11160-11165.
36. Marcar L., Maclaine N.J., Hupp T.R., Meek D.W. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res 2010, 70:10362-10370.
37. Yang B., O'Herrin S.M., Wu J., Reagan-Shaw S., Ma Y., Bhat K.M., et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 2007, 67:9954-9962.
38. Nardiello T., Jungbluth A.A., Mei A., Diliberto M., Huang X., Dabrowski A., et al. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of surviving. Clin Cancer Res 2011, 17:4309-4319.
39. Feng Y., Gao J., Yang M. When MAGE meets RING: insights into biological functions of MAGE proteins. Protein Cell 2011, 2:7-12.
40. Bai S., He B., Wilson E.M. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol 2005, 25:1238-1257.
41. Bai S., Wilson E.M. Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol 2008, 28:1947-1963.
42. Askew E.B., Bai S., Hnat A.T., Minges J.T., Wilson E.M. Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators. J Biol Chem 2009, 284:34793-34808.
43. Askew E.B., Bai S., Blackwelder A.J., Wilson E.M. Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling. J Biol Chem 2010, 285:21824-21836.
44. Karpf A.R., Bai S., James S.R., Mohler J.L., Wilson E.M. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 2009, 7:523-535.
45. Aprelikova O., Pandolfi S., Tackett S., Ferreira M., Salnikow K., Ward Y., et al. Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res 2009, 69:616-624.
46. Sakurai T., Itoh K., Higashitsuji H., Nagao T., Nonoguchi K., Chiba T., et al. A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem 2004, 279:15505-15514.
47. Peikert T., Specks U., Farver C., Erzurum S.C., Comtair S.A. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res 2006, 66:4693-4700.
48. Nagao T., Higashitsuji H., Nonoguchi K., Sakurai T., Dawson T., Mayer R.J., et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem 2003, 278:10668-10674.
49. Bandić D., Juretić A., Sarcević B., Šeparović V., Kujundzić-Tiljak M., Hudolin T., et al. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J 2006, 47:32-41.
50. Kocher T., Zheng M., Bolli M., Simon R., Forster T., Schultz Thater E., et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 2002, 100:702-705.
51. Yoshida N., Abe H., Ohkuri T., Wakita D., Sato M., Noquchi D., et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 2006, 28:1089-1098.
52. Caballero O.L., Chen Y.T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100:2014-2021.
53. Marchand M., Van Baren N., Weynants P., Brichard V., Dréno B., Tessier M.H., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999, 80:219-230.
54. Graff-Dubois S., Faure O., Gross D.A., Alves P., Scardino A., Chouaib S., et al. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 2002, 169:575-580.
55. Serrano A., Tanzarella S., Lionello I., Mendez R., Traversari C., Ruiz-cabello F., et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int J Cancer 2001, 94:243-251.
56. Goodyear O., Agathanggelou A., Novitzky-Basso I., Siddigue S., McSkeane T., Ryan G., et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010, 116:1908-1918.
57. Tyagi P., Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009, 10:371-374.